{"nctId":"NCT01471171","briefTitle":"Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","startDateStruct":{"date":"2011-11"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"count":112,"armGroups":[{"label":"Aclidinium bromide","type":"EXPERIMENTAL","interventionNames":["Drug: Aclidinium Bromide"]},{"label":"Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Aclidinium Bromide","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult male and female patients aged ≥ 40 with stable moderate to severe COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines).\n* Post-salbutamol Forced Expiratory Volume in one second(FEV1) \\< 80% and ≥ 30% of predicted normal value and Post-salbutamol FEV1/Forced Vital Capacity (FVC) \\< 70%.\n* Current or ex-smokers of ≥ 10 pack-years\n* Functional residual capacity (FRC) measured by body plethysmography at Screening Visit ≥ 120% of predicted value\n\nExclusion Criteria:\n\n* History or current diagnosis of asthma\n* Signs of an exacerbation within 6 weeks ( or 3 months if results in hospitalisation) prior to the screening visit or during the run-in period.\n* Clinically significant respiratory and/or cardiovascular conditions or laboratory abnormalities.\n* Conditions where the use of anticholinergic drugs is contraindicated, such as known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma.\n* Patients with an oxygen saturation \\< 85% during cycle exercise on room air at Screening Visit, Run- in Visit and Visit 1.\n* Contra-indications of cardiopulmonary exercise testing.\n* Patient who in the investigator's opinion will need to start a pulmonary rehabilitation program during the study and/or patients who have just started/finished pulmonary rehabilitation at least 3 months prior to the Screening Visit.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Endurance Time (Seconds)","description":"Change from baseline in endurance time during constant work rate cycle ergometry to symptom limitation at 75% of Maximum Work load (Wmax) after 3 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.3","spread":"18.8"},{"groupId":"OG001","value":"9.8","spread":"19.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Trough Inspiratory Capacity (IC) (Litres)","description":"Change from baseline in trough IC after 3 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.098","spread":"0.024"},{"groupId":"OG001","value":"0.020","spread":"0.025"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Intensity of Dyspnoea","description":"Change from baseline in intensity of dyspnoea based on the Borg CR10 Scale® (ranging from '0'=nothing at all to '10'=extremely strong/maximal dyspnoea, the highest possible numerical value) at isotime during constant work rate cycle ergometry after 3 weeks of treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.48","spread":"0.20"},{"groupId":"OG001","value":"0.15","spread":"0.20"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":111},"commonTop":["Nasopharyngitis"]}}}